Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
4.300
+0.100 (+2.38%)
Streaming Delayed Price
Updated: 11:56 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about ZyVersa Therapeutics, Inc. - Common Stock
< Previous
1
2
3
Next >
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
May 15, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
April 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
April 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
February 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
February 22, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
February 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
February 07, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
January 31, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
January 24, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
January 17, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
January 10, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
January 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
January 03, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”
December 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200
December 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes
December 07, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways
December 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock
November 30, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results
November 14, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model
November 09, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation
November 06, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing
November 01, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100’s Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease
October 25, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function
October 18, 2023
From
ZyVersa Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.